BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

Gates Foundation grants Vaxxas $5M for low-dose vaccine patch   Vaxxas Pty. Ltd. received a $5 million grant Tuesday from the Bill and Melinda Gates Foundation to develop its high-density microarray patch (HD-MAP) to deliver...
BC Week In Review | Jan 12, 2018
Clinical News

PharmaMar reports OS data from Phase III of Aplidin for MM

PharmaMar S.A. (Madrid:PHM) reported data for the secondary overall survival (OS) endpoint from the Phase III ADMYRE trial in 255 patients with relapsed or refractory multiple myeloma (MM) evaluating Aplidin plitidepsin plus dexamethasone vs. dexamethasone...
BC Week In Review | Dec 22, 2017
Clinical News

CHMP recommends against PharmaMar's Aplidin for MM

EMA's CHMP recommended against approval of Aplidin plitidepsin from PharmaMar S.A. (Madrid:PHM) to treat relapsed or refractory multiple myeloma. The committee said it will publish more information on the opinion "shortly." Chugai Pharmaceutical Co. Ltd....
BC Extra | Dec 15, 2017
Company News

CHMP recommends basket of therapies

EMA's CHMP recommended approval of a host of therapies, including Alofisel darvadstrocel (Cx601) to treat Crohn's disease, Ozempic semaglutide (NN9924, OG217SC) to treat Type II diabetes, Herzuma biosimilar trastuzumab to treat breast and gastric cancer...
Items per page:
1 - 4 of 4